MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Ophthalmology, Optometry & Ocular Health (BioPharmaceuticals & Biotechnology)
Annexon Biosciences, Inc.(NASDAQ: ANNX)
Organization & Developments: Annexon
Parents
Annexon Biosciences, Inc.(NASDAQ: ANNX)
Children
*ANX005 for serious CNS and autoimmune disorders and ANX007 for ophthalmic disorders, both inhibit a protein known as C1q, which is the initiating molecule of the classical pathway, and blocks the complement activation involved in neurodegeneration.
*Biopharmaceutical company focused on developing complement medicines for patients suffering from serious complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.
2016: Annexon Biosciences
2023: Annexon: ANX007 Advances Forward With Stellar Endpoint_seekingalpha.com
2024: Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
2024: Annexon previews emerging data on ANX007 for geographic atrophy
2024: Annexon Tackles Guillain-Barre, Other Inflammatory Diseases with Novel Antibody
2024: Annexon: Unforced Error Sullies Prospects
2024A: Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
2025: Annexon: Breakthrough In Guillain-Barré Faces Upcoming FDA Hurdles_ seekingalpha.com
2025: Annexon: Despite Major Catalysts, Stock Is Trading Almost At Cash
Jumps
Finance & Acquisitions: Annexon
Key People: Annexon